КАРДИОРЕНАЛЬНЫЙ СИНДРОМ 1 ТИПА

Р.Р. Калиев; М.Т Бейшенкулов; Б.Ж. Иманов; К.Р. Калиев

doi:10.54890/.v1i1.510

Р.Р. Калиев М.Т Бейшенкулов Б.Ж. Иманов К.Р. Калиев

DOI:

https://doi.org/10.54890/.v1i1.510

Аннотация

Данный обзор посвящен кардиоренальному синдрому 1 типа.

Ключевые слова:

кардиоренальный синдром, хроническая болезнь почек, биомаркеры, лечение

Библиографические ссылки

1. G. M. Virzi, S. Day, M. Cal et al. Heart-kidney crosstalk and role o f humoral signaling in critical illness. Crit Care 2014; 18(1): 201.

2. G. Viswanathan, S. Gilbert. The cardiorenal syndrome: making the connection. Int J Nephrol 2011; 2011: 283137.

3. C. Ronco, M. Cicoira, P. A. McCullough. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting o f acutely decompensated heart failure. J Am Coll Cardiol 2012; 60: 1031-1042.

4. C. Ronco, M. Haapio, A.A. House et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539.

5. M. Haase, C. Muller, K. Damman et al. Pathogenesis o f cardiorenal syndrome type 1 in acute decompensated heart failure: workgroup statements from the eleventh consensus conference o f the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2013; 182: 99-116.

6. Y. Ismail, Z. Kasmikha, H.L. Green et al. Cardiorenal syndrome type 1: epidemiology, pathophysiology, and treatment. Semin Nephrol 2012; 32: 18 25.

7. K. W. Prins, T. Thenappan, J. S. Markowitz et al. Cardiorenal syndrome type 1: renal dysfunction in acute decompensated heart failure. J Clin Outcomes Manag 2015; 22: 443-454.

8. G. C. Fonarow, K. F. Adams, W. T. Abraham et al. ADHERE Scientific Advisory Committee, Study Group, and nvestigators. Risk stratification for inhospital mortality in acutely decompensated heart failure: Classification and regression tree nalysis. JAMA 2005; 293:572-80.

9. B. B. Newsome, D. G. Warnock, W. M. McClellan et al. Longterm risk o f mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med 2008; 168: 609-16.

10. A. Goldberg, E. Kogan, H. Hammerman et al. Impact o f transient and persistent acute kidney injury on long-term outcomes after acute myocardial infarction. Kidney Int 2009; 76: 900-6.

11. Z. Eren, O. Ozveren, E. Buvukoner et al. A singlecentre study o f acute Cardiorenal syndrome: inci dence, risk factors and consequences. Cardiorenal Med 2012; 2: 168-176.

12. G. M. Virzi, A. Clementi, A. Brocca et al. The hemodynamic and nonhemodynamic crosstalk in cardiorenal syndrome type 1. Cardiorenal Med 2014; 4:103-112.

13. S. Bhandari, P. Jain. Management o f acute coronary syndrome in chronic kidney disease. J Assoc Physicians India 2012; 60: 48-51.

14. M. Givertz, J.R. Teerlink, N.M. Albert et al. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail 2013; 19: 371-389.

15. G. Lazaros, D. Tsiachris, D. Tousoulis et al. Inhospital worsening renal function is an independent predictor o f one-year mortality. Am Heart Journal 2010; 160: 1065-1071.

16. A. P. Amin, J. A. Spertus, K. J. Reid et al. The prognostic importance o f worsening renal function during an acute myocardial infarction on long-term mortality. Am Heart J 2010; 160: 1065-1071.

17. A. Granfeldt. Organ dysfunction following regional and global ischemia/reperfusion. Intervention with postconditioning and adenocaine. Dan Med J 2012; 59: B4496.

18. M. J. Hsieh, Y. C. Chen, C. C. Chen et al. Renal dysfunction on admission, worsening renal function, and severity o f acute kidney injury predict 2- year mortality in patients with acute myocardial infarction. Circ J 2013; 77: 2017-223.

19. Y. Yang, Y. Wang, Z. Shi et al. Association o f E/E' and NT-proBNP with Renal Function in Patients with Essential Hypertension. PLoS One 2013; 8(1): e54513.

20. R. T. Cole, A. Masoumi, F. Triposkiadis et al. Renal dysfunction in heart failure. Med Clin North Am 2012; 96: 955-974.

21. S. M. Udani, J. L. Koyner. The effects o f heart failure on renal function. Cardiol Clin 2010; 28: 453 465.

22. A. Ahmed, M.W. Rich, P. W. Sanders et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol 2007; 99: 393-398.

23. V. Carubelli, C. Lombardi, E. Gorga et al. Cardiorenal interactions. Heart Fail Clin 2016; 12: 335 347.

24. D. N. Cruz. Cardiorenal syndrome in critical care: the acute cardiorenal and renocardiac syndromes. Adv Chronic Kidney Dis 2013; 20: 56-66.

25. M. Jessup, M. R. Costanzo. The cardio-renal syndrome: do we need a change in strategy or a change o f tactics? J Am Coll Cardiol 2009; 53: 597-9.

26. G. M. Virzi, R. Torregrossa, D.N. Cruz et al. Cardiorenal syndrome type 1 may be immunologically mediated: A pilot evaluation o f monocyte apoptosis. Cardiorenal Med 2012; 2:33-42.

27. G. M. Virzi, A. Clementi et al. Oxidative stress: Dual pathway induction in cardiorenal syndrome type 1 pathogenesis. Oxid Med Cell Longev 2015; 391790.

28. E. Cho, M. Kim, Y. S. Ko et al. Role o f inflammation in the pathogenesis o f cardiorenal syndrome in a rat myocardial infarction model. Nephrol Dial Transplant 2013; 28:2766-78.

29. P. Devarajan. Neutrophil gelatinase-associated lipocalin: A troponin-like biomarker for human acute kidney injury. Nephrology (Carlton) 2010; 15:419-28.

30. C. Soyler, M. D. Tanriover, S. Ascioglu et al. Urine neutrophil gelatinase-associated lipocalin levels predict acute kidney injury in acute decompensated heart failure patients. Ren Fail 2015; 37:772-776.

J. Lassus, V. P. Harjola, R. Sund et al. FINN-AKVA Study group. Prognostic value o f cystatin C in acute heart failure in relation to other markers o f renal function and NT-proBNP. Eur Heart J 2007; 28:1841-1847.

32. T. Arimoto, Y. Takeishi, T. Niizeki et al. Cystatin C, a novel measure o f renal function, is an independent predictor o f cardiac events in patients with heart failure. J Card Fail 2005; 11:595-601.

33. S. Manzano-Fernandez, M. Boronat-Garcia, M. D. Albaladejo-Oton et al. Complementary prognostic value o f cystatin C, N-terminal pro-B-type natriuretic peptide and cardiac troponin T in patients with acute heart failure. Am J Cardiol 2009; 103:1753-1759.

34. G. M. Felker, K. L. Lee, D. A. Bull et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364:797-805.

35. A. K. Chung, P. S. Pang, G. C. Fonarow. Acute heart failure syndromes: Potential strategies to improve post-discharge outcomes. Curr Treat Options Cardiovasc Med 2008; 10(4): 349-57.

36. A. Mebazaa, M. S. Nieminen, M. Packer et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE randomized trial. JAMA 2007; 297:1883-1891.

37. G. Giamouzis, J. Butler, R. C. Starling et al. Impact o f dopamine infusion on renal function in hospitalized heart failure patients: Results o f the dopamine in acute decompensated heart failure (DAD-HF) trial. J Card Fail 2010; 16:922-930.

38. H. H. Chen, K. J. Anstrom, M. M.Givertz et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The ROSE acute heart failure randomized trial. JAMA 2013; 310:2533-2543.

39. R. M. Witteles, D. Kao, D. Christopherson et al. Impact o f nesiritide on renal function in patients with acute decompensated heart failure and preexisting renal dysfunction a randomized, doubleblind, placebo-controlled clinical trial. J Am Coll Cardiol 2007; 50:1835-1840.

40. C. M. O ’Connor, R. C. Starling, A. F. Hernandez et al. Effect o f nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32-43.

41. M. M. Givertz, B. M. Massie, T. K. Fields et al. CKI-201 and CKI-202 Investigators. The effects of KW-3902, an denosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007; 50: 1551-1560.

42. B. M. Massie, C. M. O ’Connor, M. Metra et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010; 363:1419-1428.

43. A. A. Voors, H. C. Dittrich, B. M. Massie et al. Effects o f the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: Results from PROTECT (placebo-controlled randomized study of the selective adenosine A1 receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function). J Am Coll Cardiol 2011; 57:1899-1907.

44. S. S. Gottlieb, M. M. Givertz, M. Metra et al. The effects o f adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: The REACH UP study. J Card Fail 2010; 16:714-719.

45. M. R. Costanzo, M. E. Guglin, M. T. Saltzberg et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49:675-83.

46. B. A. Bart, S. R. Goldsmith, K. L. Lee et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367:2296 2304.

47.B. Ebrahim, K. Sindhura, J. Okoroh et al. Metaanalysis o f ultrafiltration versus diuretics treatment option for overload volume reduction in patients with acute decompensated heart failure. Arq Bras Cardiol 2015; 104:417-425.

48. J. S. Kwong, C. M. Yu. Ultrafiltration for acute decompensated heart failure: A systematic review and meta-analysis o f randomized controlled trials. Int J Cardiol 2014; 172:395-402.